Cafepharma | Pharmaceutical Sales, Medical Sales, Lab Sales

Cafepharma Today

December 13 2019 - FDA approves Sarepta’s DMD drug that it had previously rejected

FDA approves Sarepta’s DMD drug that it had previously rejected
Biogen chalks up another failure
3M sells off its drug delivery business
The House passes the Lower Drug Costs Now Act, but it’s unlikely to become law
*please scroll down for all the latest news*

Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe

Today's most popular searches:

Current News

submit a press release

Click here to stay updated on CP happenings

GSK's ViiV seeks marketing license for baby-friendly HIV pill

Reuters

Sunday, December 15, 2019 - 12:23am

tags:

GSK, HIV, Dolutegravir, pediatric

PhRMA sues Oregon over drug-pricing transparency laws

Beckers Hospital Review

Sunday, December 15, 2019 - 12:21am

tags:

PhRMA, Oregon, drug pricing, legislation

Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning

Motley Fool

Sunday, December 15, 2019 - 12:15am

tags:

Sanofi, M&A, immuno-oncology, Lantus, diabetes

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Fierce Pharma

Friday, December 13, 2019 - 9:36pm

tags:

Amarin, Vascepa, FDA, Cardiovascular

FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug

Endpoints

Friday, December 13, 2019 - 9:32pm

tags:

FDA, advisory panels, Horizon Therapeutics, thyroid eye disease, teprotumumab

Gritstone posts 'one of the most potent immunogenic-responses for a neoantigen vaccine'

Fierce Biotech

Friday, December 13, 2019 - 9:19pm

tags:

Gritstone Oncology, solid tumors, vaccines, neoantigens

FDA Finalizes Rule to Go From Paper to Electronic Device Submissions

RAPS.org

Friday, December 13, 2019 - 9:13pm

tags:

Bristol-Myers wins $752 million in U.S. patent case against Gilead

Reuters

Friday, December 13, 2019 - 9:09pm

tags:

Bristol-Myers Squibb, Gilead Sciences, Kite Pharma, patents, Juno Therapeutics

Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga

Fierce Pharma

Friday, December 13, 2019 - 9:05pm

tags:

Eli Lilly, Boehringer Ingelheim, Jardiance, Farxiga, diabetes, AstraZeneca, heart failure

In stunning twist, FDA approves Sarepta's Duchenne drug it rejected

Biopharma Dive

Friday, December 13, 2019 - 12:28pm

tags:

FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy, Vyondys 53

Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's

Fierce Biotech

Friday, December 13, 2019 - 12:26pm

tags:

Biogen, Alzheimer's disease, aducanumab, progressive supranuclear palsy, gosuranemab, clinical trials

FDA Approves Pfizer's Extended Release Xeljanz for Ulcerative Colitis

BioSpace

Friday, December 13, 2019 - 12:21pm

tags:

Pfizer, Xeljanz XR, FDA, ulcerative colitis

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

Pharmaceutical Business Review

Friday, December 13, 2019 - 12:20pm

tags:

Roche, Perjeta, Herceptin, HER2+ breast cancer, SABCS, breast cancer

The House passed Pelosi's drug pricing bill, but don't expect it to become law

Fierce Pharma

Friday, December 13, 2019 - 12:15pm

tags:

legislation, drug pricing, Lower Drug Costs Now Act of 2019

Attorney misconduct allegations crop up in Johnson & Johnson, Gilead cases

Fierce Pharma

Friday, December 13, 2019 - 12:13pm

tags:

attorneys, JNJ, Gilead Sciences

Biopharma has abandoned antibiotic development. Here’s why we did, too.

Endpoints

Friday, December 13, 2019 - 11:16am

tags:

Octagon Therapeutics, drug discovery, drug development, antibiotics

BioDelivery Sciences turns invisible pain into high-color art for gallery show

Fierce Pharma

Friday, December 13, 2019 - 11:05am

tags:

BioDelivery Sciences, pain, invisible pain

Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

EP Vantage

Friday, December 13, 2019 - 11:02am

tags:

Axsome Therapeutics, AXS-05, treatment-resistant depression, depression, Eli Lilly, pegilodecakin, lung cancer

Anixa delays CAR-T trial in bid to boost efficacy

Fierce Biotech

Friday, December 13, 2019 - 11:00am

tags:

Anixa Biosciences, ovarian cancer, CAR-T

3M Sheds Its Drug-Delivery Business

Medical Devices and Diagnostics Industry

Friday, December 13, 2019 - 10:56am

tags:

3M, M&A, drug delivery, Altaris Capital

Pages

Latest CP Wire Articles

[release] ACTO Achieves 158% Year to Date Revenue Growth in 2019 and Has Digitally Transformed Over 50 Life Sciences Companies

MedReps survey finds best companies to work for in 2020

[release] eyeforpharma Awards Recognize Two ACTO Use Cases as Finalists

Karuna Therapeutics Files for $52 Million Offering

Biocept Files for $27 Million Offering

Highlights: 2019 Cardiometabolic Health Congress, Chicago IL

Microbiome Report

TELA Bio Files for $69 Million IPO

Oyster Point Pharma Files for $85 Million IPO

Cabaletta Bio Files for $100 Million IPO

Latest Pharmagather Articles

Year in Review: R&D, Regulatory, and Reimbursement Hurdles

pharmexec r&d

The AI Boom in Healthcare: How Manufacturers Can Prepare

pharmexec technology

New Report on Melanoma Research: 3 Key Findings

Elsevier

Sticking Together in Solution

In the Pipeline

Insurers + PBMs + Specialty Pharmacies + Providers: Will Vertical Consolidation Disrupt Drug Channels in 2020?

Drug Channels

Healthy China initiative emphasizes prevention

Elsevier

Arguments on Drug Pricing

In the Pipeline

PharmaPendium Team Collaborates with Pharma Companies on Drug-Drug Interaction Risk Calculator

Elsevier

The Hype Problem

In the Pipeline

Pharma Jobs from Indeed

Indeed